GLAUPREXA Trademark

Trademark Overview


On Tuesday, March 21, 2017, a trademark application was filed for GLAUPREXA with the United States Patent and Trademark Office. The USPTO has given the GLAUPREXA trademark a serial number of 87379490. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, January 4, 2021. This trademark is owned by Allergan, Inc.. The GLAUPREXA trademark is filed in the Pharmaceutical Products category with the following description:

Oral, transdermal, injectable and intravaginal contraceptive preparations; intravaginal contraceptive sponge; Hormone replacement therapy preparations; Pharmaceutical preparations for the prevention of preterm birth or pregnancy; Pharmaceutical preparations for the treatment and prevention of urinary incontinence and overactive bladder; Pharmaceutical preparations for the treatment and prevention of iron deficiency and anemia; Pharmaceutical preparations for the treatment and prevention of osteoporosis; Pharmaceutical preparations for the treatment and prevention of endometriosis; Pharmaceutical preparations for the treatment and prevention of symptoms associated with uterine fibroids; Iron chelating pharmaceutical preparations; Fertility enhancing preparations; Pharmaceuticals and medicines for the treatment and prevention of sexual dysfunction; Pharmaceuticals and medicines for the prevention and treatment of conditions affecting sensory organs; Pharmaceuticals and medicines for the ...
glauprexa

General Information


Serial Number87379490
Word MarkGLAUPREXA
Filing DateTuesday, March 21, 2017
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, January 4, 2021
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, June 6, 2017

Trademark Statements


Goods and ServicesOral, transdermal, injectable and intravaginal contraceptive preparations; intravaginal contraceptive sponge; Hormone replacement therapy preparations; Pharmaceutical preparations for the prevention of preterm birth or pregnancy; Pharmaceutical preparations for the treatment and prevention of urinary incontinence and overactive bladder; Pharmaceutical preparations for the treatment and prevention of iron deficiency and anemia; Pharmaceutical preparations for the treatment and prevention of osteoporosis; Pharmaceutical preparations for the treatment and prevention of endometriosis; Pharmaceutical preparations for the treatment and prevention of symptoms associated with uterine fibroids; Iron chelating pharmaceutical preparations; Fertility enhancing preparations; Pharmaceuticals and medicines for the treatment and prevention of sexual dysfunction; Pharmaceuticals and medicines for the prevention and treatment of conditions affecting sensory organs; Pharmaceuticals and medicines for the prevention and treatment of conditions affecting the central nervous system; Pharmaceuticals and medicines for the prevention and treatment of conditions affecting urogenital organs; Pharmaceuticals and medicines for the prevention and treatment of conditions affecting circulatory systems; Pharmaceuticals and medicines for the treatment of cardiovascular disease and blood pressure; Pharmaceutical preparations for the treatment and prevention of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceuticals and medicines for the treatment and prevention of irritable bowel syndrome; Pharmaceutical preparations that support, encourage or promote bone strength or bone health or which are used in the treatment of bone disorders or bone diseases; Antibiotics; Antifungal preparations; Antivirals and Antiprotozoals; Pharmaceutical preparations for the prevention and treatment of bacterial infections; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of hypertension; Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease, dementia, AIDS-related dementia, neurological disorders, neurodegenerative disorders, and depression, neuroprotective agent; antidepressants; coronary vasodilating agents; Pharmaceutical preparations for the treatment of hypothyroidism; Pharmaceuticals used in connection with anti-aging, the treatment of glabellar lines, facial wrinkles, asymmetries and defects and conditions of the human skin, facial aesthetic surgery, facial aesthetic reconstruction, breast aesthetics; topical antibiotics, anti-inflammatory, anti-infective, anti-glaucoma and decongestant formulations; sterile antibiotic and anti-inflammatory ointments; ocular wetting solutions, namely, eye drops, artificial tears and gels for the treatment of minor ocular inflammations and allergic conditions; Pharmaceutical preparations for the treatment of neurological disorders, muscle dystonias, smooth muscle disorders, autonomic nerve disorders, headaches, hyperhydrosis, sports injuries, cerebral palsy, spasms, tremors and pain; dermatological formulations, namely, medicated dry skin lotions and creams, acne medications and medicated skin lighteners; Pharmaceuticals and cosmeceuticals, namely, medicated skin cleansers, toners, moisturizers, rejuvenators, rehydrating creams, and lotions for the face and body

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, March 24, 2017
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameAllergan, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressIrvine, CA 92612

Party NameAllergan, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressIrvine, CA 92612

Trademark Events


Event DateEvent Description
Monday, January 4, 2021ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, January 4, 2021ABANDONMENT - NO USE STATEMENT FILED
Thursday, April 16, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, April 15, 2020EXTENSION 5 GRANTED
Monday, April 13, 2020EXTENSION 5 FILED
Wednesday, April 15, 2020CASE ASSIGNED TO INTENT TO USE PARALEGAL
Monday, April 13, 2020TEAS EXTENSION RECEIVED
Friday, November 8, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, November 6, 2019EXTENSION 4 GRANTED
Wednesday, November 6, 2019EXTENSION 4 FILED
Wednesday, November 6, 2019TEAS EXTENSION RECEIVED
Thursday, March 14, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, March 12, 2019EXTENSION 3 GRANTED
Tuesday, March 12, 2019EXTENSION 3 FILED
Tuesday, March 12, 2019TEAS EXTENSION RECEIVED
Tuesday, October 30, 2018NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, October 26, 2018EXTENSION 2 GRANTED
Friday, October 26, 2018EXTENSION 2 FILED
Friday, October 26, 2018TEAS EXTENSION RECEIVED
Wednesday, May 2, 2018NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, April 30, 2018EXTENSION 1 GRANTED
Monday, April 30, 2018EXTENSION 1 FILED
Monday, April 30, 2018TEAS EXTENSION RECEIVED
Tuesday, November 28, 2017NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Sunday, October 15, 2017EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED
Saturday, July 15, 2017CHANGES/CORRECTIONS AFTER PUB APPROVAL ENTERED
Wednesday, July 12, 2017ASSIGNED TO PETITION STAFF
Friday, July 7, 2017TEAS POST PUBLICATION AMENDMENT RECEIVED
Wednesday, June 28, 2017EXTENSION OF TIME TO OPPOSE RECEIVED
Tuesday, June 6, 2017OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, June 6, 2017PUBLISHED FOR OPPOSITION
Wednesday, May 17, 2017NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Thursday, April 27, 2017APPROVED FOR PUB - PRINCIPAL REGISTER
Monday, April 24, 2017ASSIGNED TO EXAMINER
Friday, March 24, 2017NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Friday, March 24, 2017NEW APPLICATION ENTERED IN TRAM